Acute lymphoblastic leukemia (ALL) is the most common malignant disease in children. Despite the high rates of remission induction and survival achieved with current treatment regimens, a subset of patients do not respond well to therapy. These patients either fail induction therapy or relapse after a short remission. The molecular basis for the refractory disease encountered in these patients has not been elucidated. Previous studies including ours have found that ALL cells may express certain cytokines, and that aberrant expression of endogenous cytokines such as tumor necrosis factor a (TNFa) may be associated with refractory disease. 1, 2 In our studies of two ALL cell lines differing in expression of endogenous TNF (enTNF), we have previously reported that enTNF expression was associated with resistance to recombinant (r) TNFa. 2 We later performed a series of studies on the phenotypes and drug sensitivity of these two lines (enTNF þ EU-1 and enTNF À EU-3), and found that although both EU-1 and EU-3 displayed similar immunophenotypes and certain molecular properties such as p53 status and expression of MDM2 and Bcl-2, only EU-1 was resistant to radiation-and doxorubicin-induced apoptosis.
3,4 As EU-1 but not EU-3 expresses a high level of enTNF, we hypothesized that enTNF may be one of the survival factors conferring resistance to radiation and doxorubicin.
Tumor necrosis factor a is a pleiotropic cytokine that exerts a wide variety of biological effects. In particular, TNFa can have proliferative and/or survival effects on 'normal' untransformed cells as well as some human tumor cells, as opposed to antiproliferative, apoptotic and cytotoxic effects on other tumors both in vitro and in vivo.
5 The biological activity of TNFa is mediated by binding of specific receptors expressed on the surface of multiple cell types. There are two types of TNF receptors (TNFR1 and TNFR2). TNFR1 mainly induces apoptotic signaling, whereas TNFR2 predominantly regulates survival signaling. The interaction between TNFa and TNFR2 results in binding of TNFR-associated factor 2 (TRAF2) and receptor interactive protein (RIP). Tumor necrosis factor receptor-associated factor 2 and RIP stimulate pathways leading to activation of survival signaling such as the NF-kB pathway.
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Tumor necrosis factor a is also known to induce cell-survival signaling by activating the phosphatidylinositol-3 kinase (PI3K)-Akt (protein kinase B) pathway. 7 Activation of Akt entails a complex series of events involving additional proteins. Phosphatidylinositol-3 kinase-generated lipid products PI 3,4,5 P 3 and PI 3,4 P 2 recruit Akt to the plasma membrane, where the threonine 308 and serine 473 residues of Akt are phosphorylated and activated. Activated Akt exerts antiapoptotic effects through phosphorylation of substrates that directly regulate the apoptotic machinery such as Bad and caspase-9, or phosphorylation of substrates that indirectly inhibit apoptosis such as IKKa and MDM2. Unlike the pathway of NF-kB activation by TNFa, the mechanism for TNFa induction of the PI3k/Akt pathway remains largely unclear.
Studies have shown that certain neoplastic cells including ALL constitutively produce TNFa and that enTNF is associated with resistance to exogenous TNFa/rTNFa-induced cytotoxicity. enTNF þ tumor cells are resistant not only to rTNFa but also to chemotherapeutic drugs such as doxorubicin, and enTNF produced by neoplastic cells is associated with disease progression. The mechanisms for enTNF-induced cell survival and resistance to apoptosis are not yet clear. As TNFa can activate the PI3K-Akt pathway, we investigated whether the survival and antiapoptotic function of enTNF are through induction of PI3K-Akt.
The results of our studies on ALL cell lines indicate that enTNF is associated with activation of Akt. We examined EU-1 and EU-3 by Western blot to detect phosphorylation of Akt on Ser 473 (p-Akt) as a marker for activation. As shown in Figure 1a , enTNF þ EU-1 cells expressed high levels of constitutive p-Akt, whereas enTNF À EU-3 cells were negative for p-Akt when cultured in medium without stimulation. Treatment of EU-1 cells with a specific PI3K inhibitor, Ly294002, significantly downregulated p-Akt expression in this line (Figure 1b) .
To further evaluate whether enTNF produced by EU-1 cells activates Akt, we treated enTNF À EU-3 cells with conditioned medium (supernatant) from EU-1 cultures, and examined whether neutralization of enTNF and TNFRs blocks Akt activation. EU-1 supernatant has been shown to contain secreted active TNFa as detected by our previous experiments. 2 As shown in Figure 1c , treatment of EU-3 cells with EU-1 supernatant as well as with rTNFa rapidly (0.5-1 h) induced expression of p-Akt. Treatment with neutralizing anti-TNFa monoclonal antibody inhibited both constitutive p-Akt in EU-1 cells and EU-1 supernatant-induced p-Akt in EU-3 cells (Figure 1d and e). The expression of pro-Akt (Akt) in EU-1 cells treated with anti-TNF antibody, and in EU-3 cells treated with either EU-1 supernatant or TNF antibody, remained unchanged.
In our experiments, cell death was not observed in EU-3 cultured with EU-1 supernatant (data not shown), which was presumably due to the existence of other unknown growth factors and cytokines in the supernatant, which abrogated the cytotoxic effect of enTNF on EU-3 cells. Also, activation of Akt in EU-3 cells by EU-1 supernatant was not due to unknown growth factors or cytokines in the supernatant, as neutralizing antibody against enTNF in EU-1 supernatant abolished Akt activation in the supernatant-treated EU-3 cells.
In order to test whether enTNF produced by EU-1 stimulates Akt activation through regulation of TNFRs, we treated both EU-1 and EU-3 with neutralizing anti-TNFR antibodies. We first examined the expression of both TNFR1 and TNFR2 in EU-1 and EU-3 cells. As shown in Figure 2a , EU-1 and EU-3 cells expressed similar levels of both TNFR1 and TNFR2. The expression of p-Akt in EU-1 cells was significantly downregulated by treatment with anti-TNFR2 but not with anti-TNFR1 antibodies ( Figure 2b ). Similarly, p-Akt in EU-3 cells induced by EU-1 supernatant was inhibited by anti-TNFR2 antibody ( Figure 2c ). Thus, activation of Akt in these lines was mediated by TNFR2.
Unlike the pathway of NF-kB activation by TNFa, which is predominantly regulated via TNFR2, the mechanism for TNFa induction of the PI3k/Akt pathway remains unclear. A recent study using a model of retinal ischemia-reperfusion demonstrated opposing actions of the two TNFRs, with TNFR1 aggravating neuronal damage and TNFR2 promoting neuroprotection via the PI3K-Akt pathway.
8 Consistent with this observation, our results suggest that enTNF may utilize TNFR2-mediated signaling to induce Akt as well as NF-kB, and interaction between NF-kB and Akt may play an important role in regulating cell growth and resistance to apoptosis. It has been reported that PI3K plays a pivotal role in TNF-mediated Letters to the Editor activation of NF-kB-dependent genes, and a dominant-negative mutant of the p85 regulatory subunit of PI3K effectively blocked TNF-induced expression of an NF-kB-dependent reporter gene. We are currently evaluating enTNF-induced activation of NF-kB and its involvement in the PI3K/Akt-regulated survival pathway in ALL cells.
To obtain direct evidence that constitutive Akt activation and cell survival resulted from enTNF, we examined whether inhibition of enTNF by siRNA would decrease p-Akt expression and suppress cell growth. We have generated a pSUPER/TNF siRNA plasmid containing a 19-nt siRNA sequence specific for targeting TNFa (Figure 3a) . Transfection of this plasmid into EU-1 cells suppressed approximately 40-60% expression of the enTNF in three stable selected clones. Corresponding to inhibition of enTNF, the expression of p-Akt in these cell clones was downregulated (Figure 3b) .
As constitutive activation of Akt is associated with cell proliferation and growth, we performed a clonogenic assay to compare the colony-forming ability of EU-1 cells transfected with either pSUPER/TNF siRNA or with pSUPER vector (control). EU-1 transfected with pSUPER/TNF siRNA showed significantly decreased colony-forming ability compared to EU-1 control cells. As shown in Figure 3c , approximately 120 colonies were formed by EU-1/pSUPER TNF siRNA compared to about 150 from EU-1 control cells when 10 4 cells were seeded and cultured for 7 days. The cell numbers of each colony from EU-1/ pSUPER/TNF siRNA were generally less than that from control cells (data not shown). As also shown in Figure 3c , the decrease in colony numbers following incubation with doxorubicin was more obvious in EU-1/pSUPER/TNF siRNA cells as compared to control cells (Po0.05). However, addition of Ly294002 to the cultures significantly suppressed colony formation by EU-1 control cells compared to EU-1 cells transfected with TNF siRNA (Po0.01). This suggests that enTNF is able to increase the proliferation of EU-1 cells as well as their resistance to doxorubicin.
We further compared the sensitivity of EU-1 cells transfected with pSUPER/TNF siRNA and EU-1 control cells to doxorubicin-induced cell death and apoptosis in the presence or absence of Ly294002. Consistent with the results of the clonogenic assay, EU-1 cells transfected with pSUPER/TNF siRNA became more sensitive to doxorubicin than were the EU-1 control cells. As shown in Figure 4a and b, a significant difference between EU-1/TNF siRNA and EU-1/control cells was noted in mean cell survival after 48 h treatment with doxorubicin concentrations of 0.5 mM and greater (Po0.05). Although the PI3K inhibitor Ly294002 alone did not show an obviously inhibitory effect on either TNF/siRNA-transfected or control cells, addition of Ly294002 to doxorubicin significantly increased the cytotoxic effect of doxorubicin on control cells compared to EU-1 cells transfected with TNF/siRNA. Consistent with these observations, a flow-cytometric apoptosis assay showed a significantly increased percentage of EU-1/control cells treated with combined doxorubicin and Ly294002 (from 7 to 63%) were annexin-V positive at 36 h post treatment, as compared to doxorubicin alone (from 7 to 13.5%) (Figure 4c ).
The expression of enTNF by neoplastic cells may have important clinical consequences in acute leukemia. A previous study has demonstrated that patients who failed to respond to chemotherapy showed relatively high levels of enTNF expression in their leukemic cells in 19 cases (six ALL and 13 AML). 1 The expression of enTNF by primary ALL cells from patients, and the association between enTNF expression and response to chemotherapy, needs to be evaluated in a larger number of cases to determine whether enTNF expression is a predictor of clinical outcome. Our studies on leukemia cell lines have indicated that the important PI3K-Akt survival signaling pathway is activated by enTNF, leading to significantly increased cell growth and resistance to chemotherapy. Understanding the mechanism by which enTNF activates Akt may provide a basic framework for the rational design of new agents for treating refractory leukemia. For example, specific inhibitors to suppress PI3K-Akt activation or synthetic siRNA to directly silence enTNF might be useful for the treatment. Recent studies have highlighted the power of array-based comparative genomic hybridization (aCGH) to characterize chromosomal imbalances in mantle cell lymphoma (MCL). [1] [2] [3] Several of the deletions detected in these studies, including losses in 1p, 8p, 9q, 9p, 13q and 17p, have been shown to correlate with prognosis. 1, 2 It is widely assumed that chromosomal deletions exert their pathogenic effect through inactivation of tumor suppressor genes. However, novel reports have highlighted partial uniparental disomy (pUPD) as a frequent mechanism of tumor suppressor inactivation in acute leukemias and solid tumors.
4-6 By loss of (part of) one parental chromosome and gain of the homologue from the other parent, pUPD results in loss of heterozygosity (LOH) without chromosomal deletion. As the gene dosage is not altered, pUPD cannot be detected by conventional cytogenetics, fluorescence in situ hybridization or aCGH. To investigate the role of this mechanism in MCL, we have performed genome-wide analyses of single nucleotide polymorphisms (SNPs) using a 100K SNP-array (GeneChip s Human Mapping 100K Set; Affymetrix, Santa Clara, CA, USA) in five t(11;14)-positive MCL cell lines (Granta-519, HBL-2, JEKO, REC-1 and UPN-1), which have Examples of partial uniparental disomy (pUPD) detected in mantle cell lymphoma cell lines. The profile of genomic imbalances is given as a black line with a value of 2 indicating a balanced status. The -log 10 of P-values for loss of heterozygosity (LOH) are overlaid in gray, and those exceeding 15 were considered indicative of LOH (for a better display, larger values were cut at 20). Chromosomes are shown from pter (left) to qter (right). Regions meeting the defined criteria for pUPD are underlaid by black bars.
